Unknown

Dataset Information

0

Correction: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.

ABSTRACT: Supplementary Table 1 and the Supplementary Figure legends were not included when this manuscript was first published. The files are now available here.

SUBMITTER: Lievre A 

PROVIDER: S-EPMC6079395 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.
| S-EPMC5729470 | biostudies-literature
Unknown Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.
| S-EPMC4580381 | biostudies-literature
Unknown Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.
| S-EPMC3965831 | biostudies-literature
Unknown Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study.
| S-EPMC7281759 | biostudies-literature
Unknown HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer.
| S-EPMC7914886 | biostudies-literature
Unknown Integrating anti-EGFR therapies in metastatic colorectal cancer.
| S-EPMC3712294 | biostudies-other
Unknown Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer.
| S-EPMC8176979 | biostudies-literature
Unknown Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer.
| S-EPMC7529530 | biostudies-literature
Unknown Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
| S-EPMC6246616 | biostudies-literature
Unknown RAS Amplification as a Negative Predictor of Benefit from Anti-EGFR-Containing Therapy Regimens in Metastatic Colorectal Cancer.
| S-EPMC8176984 | biostudies-literature